Amar Dixit, MD, MBA, FACAAI, FAAAI discusses how intranasal epinephrine (Neffy) presents an effective alternative to traditional autoinjectors for anaphylaxis treatment, addressing key barriers like needle phobia, device portability, and storage constraints while demonstrating comparable or superior pharmacokinetic and physiological responses to intramuscular delivery methods.
The content of this program has been supported by ARS Pharmaceuticals
EP. 2: Why Epinephrine Is the Gold Standard in Treating Anaphylaxis
May 21st 2025A panelist discusses how epinephrine is definitively the first-line treatment for anaphylaxis regardless of severity, emphasizing that delayed administration is associated with poor outcomes, including abnormal vital signs and increased risk of hospitalization.
EP. 3: Addressing Barriers to Epinephrine Use: From Reluctance to Readiness
May 21st 2025A panelist discusses how patient uncertainty about when to administer epinephrine and reluctance to use autoinjectors are major barriers to timely treatment, with over 40% not filling their prescriptions and 55% to 60% not consistently carrying their devices.
EP. 5: Epinephrine Nasal Spray: A Leap Forward in Anaphylaxis Care
May 21st 2025A panelist discusses how the newly FDA-approved intranasal epinephrine (Neffy) delivers blood concentrations and physiological responses comparable or superior to traditional intramuscular epinephrine administration methods.
EP. 6: Oral Food Challenge (OFC) Study with Epinephrine Nasal Spray
May 21st 2025A panelist discusses how a study of Neffy (epinephrine nasal spray) in Japan demonstrated effectiveness in treating 15 pediatric patients who experienced grade 2 allergic reactions during oral food challenges, with these moderate reactions including symptoms like abdominal pain, vomiting, wheezing, and mild cardiovascular effects according to the updated grading system from professional allergy societies.
EP. 7: Clinical Perspectives on Real-World Utility and Impact of Epinephrine Nasal Spray
May 21st 2025A panelist discusses how Neffy offers significant advantages over traditional autoinjectors, including longer shelf life (24-30 months), better temperature tolerance, and needle-free administration that addresses several unmet needs in anaphylaxis management.
EP. 8: Real-World Case Examples: The Impact of Epinephrine Nasal Spray
May 21st 2025A panelist discusses how real-world cases demonstrate both the effectiveness of epinephrine when properly administered and the importance of ensuring patients actually carry their medication, through the stories of a college student with cashew allergy and a child undergoing a peanut challenge.
EP. 9: Closing Thoughts on Treating Anaphylaxis with Epinephrine Nasal Spray
May 21st 2025A panelist discusses how education about anaphylaxis recognition, early epinephrine administration, and addressing barriers like device portability remains crucial, with intranasal epinephrine potentially solving many existing challenges in anaphylaxis management.